Slide 1: Investor Conference Call FY21
Investor Conference Call FY21 August 30th, 2021
Slide 2: Disclaimer
Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a leading producer of cannabinoid derived medicines. This presentation and the information contained in or accompanying this presentation are not, and are under no circumstances to be construed as, an invitation to sub
Slide 3: Rob Mitchell, CEO and Hamish White, CFO
Rob Mitchell Hamish White Kaiwhakahāere Matua Āpiha Kaiwhakahāere Pūtea Chief Executive Officer Chief Financial Officer
Slide 4: Overview
• Achievements at a Glance • Key Appointments • Financial Highlights Overview • Balance Sheet and Cashflow • Regulatory Issues • Next Milestones for Rua • Outlook 4
Slide 5: FY21: An Overview
FY21: An Overview In FY21, Rua's focus has been on building solid foundations for growth – developing the partnerships, places, processes, and people it needs to create a sustainable medicinal cannabis business model. Rua’s commitment to creating shareholder value has seen it working on two fronts -
Slide 6: Achievements at a Glance
z July, 2020 Signed sales agreement with Nimbus Health August, 2020 Granted commercial licence Achievements October, 2020 at a Glance Commissioned cultivation centre in Ruatorea Mawhiti mai ki nga whakatutukitanga October, 2020 Rua listed on NZX, raises $20 million in IPO November, 2020 Rua began it
Slide 7: Achievements at a Glance
March, 2021 Successful export of the first medicinal cannabis flower sample to Germany. Achievements June, 2021 Hyperspectral Imaging project with the University at a Glance of Waikato announced, targeting entry into the Mawhiti mai ki nga $2.5b Global cannabis testing industry. whakatutukitanga 7
Slide 8: Update on Key Milestones
Update on Key Milestones Progress Towards First Export Sales Product for New Zealand Patients Rua’s first material sales will be through Rua has been working to meet the heightened wholesale exports of pharmaceutical-grade demand for medicinal cannabis products in products into the German market via
Slide 9: Update on Key Milestones
Update on Key Milestones Progress on Cultivation Research and Development (R&D) Optimization and Capacity Rua announced a ground-breaking, two-year Discussions continue with potential grower research programme to investigate the partners to expand cultivation capacity and application of hyperspectra
Slide 10: Key Appointments
Key Appointments In FY21, our recruitment strategy focused on two equally critical components; building a capable and committed team that will propel the Company towards commercialisation; creating highly-skilled, well-paid jobs for the people of Te Tairāwhiti. 10
Slide 11: Key Appointments
Key Appointments Dr Andrea Grant Āpiha Kaihoko Matua Chief Commercial Officer PhD Molecular Neurobiology Andi has carved out an outstanding international career focused on commercialising medical innovations in the pharmaceutical and biotech sectors across the UK, Europe, USA, NZ and Asia. Andi will
Slide 12: Key Appointments
Key Appointments Dr Dawn Smith Kaiwhakahāere whanake hua Product Development Manager PhD Polymer Science Dawn joined Rua after a decade at Crown Research Institute Scion, first as Research Leader Polymers and Composites, and as Portfolio Leader Bioproducts and Packaging. Dr Smith is responsible for
Slide 13: Key Appointments
Key Appointments Len Walker Ngāti Porou, Aitanga-a-Hauiti, Te Whānau-a-Apanui Kaiwhakahāere hangahanga Production Manager MBA Len returns home having carved out an impressive management career in the Dairy industry that takes in Tui Co- operative Dairy Company, the NZ Dairy Research Institute, Edend
Slide 14: Financial Highlights: Profit & Loss
Loss before tax $6.17m Financial Investment in R&D $1.90m H ighlights Profit & Loss Nga Pūtea Other income $451k Rua’s annual financial results for the year the ended 30 June 2021. Income Tax Credit $1.75m Loss after tax $4.42m 14
Slide 15: Financial Highlights: Balance Sheet
Financial Cash & Investments was $16.4m H ighlights Balance Sheet Investment in property, plant and Nga Pūtea equipment was $6.17m Rua’s annual financial results for the year the ended 30 June 2021. Net Assets $28.8m 15
Slide 16: Financial Highlights: Cashflow
Financial Net cash outflow from operating activities $4.48m H ighlights Cashflow Net cash outflow from investing Nga Pūtea activities $14.43m Rua’s annual financial results for the year the ended 30 June 2021. Net cash inflow from financing activities $18.3m 16
Slide 17: The NZ Market
The NZ Market • April 2020 - Misuse of Drugs (Medicinal Cannabis) Regulations • The purpose of the Scheme is to improve access to quality medicinal cannabis products for patients • Licensable activities: • Cultivation • Nursery • Research • Manufacture • Supply • Domestic Market – $70m • Export Mark
Slide 18: Access in NZ
Access in NZ • Requires a prescription from a GP or specialist. • Doctors or pharmacies dispense the product. • Legally you cannot purchase medicinal cannabis products online or from a third party. • Any doctor can prescribe CBD or THC products. • Sativex is the only approved registered medical cann
Slide 19: The New Zealand Medicinal Cannabis Market
The New Zealand Medicinal Cannabis Market • Subsidies for cannabis-derived medicines. • Provisional consent for medicines with Phase 1 and 2 clinical trial data, enabling some marketing to healthcare professionals. • Low-dose CBD (which has a low-risk profile) available over the pharmacy counter. •
Slide 20: Good Manufacturing Practice
Good Manufacturing Practice • Globally recognised minimum standards for the manufacture of medicines. • Prerequisite for commercial production. • Key step on the path to revenue. • Rua began audit in November with a result due soon. 20
Slide 21: Future Milestones
Future Milestones • New Medicinal Cannabis Product Application • Stability / Shelf Life Testing • First Export Revenues • Development of the Grower Partner programme • First Cultivation Partner Production 21
Slide 22: Outlook
Outlook Join us for the Focused and realistic export strategy. AGM Clear path to revenue extending along the 12:00pm medicinal cannabis value chain. 19 October, 2021 Waikanae Surf Club, Gisborne Successful export of the first. and online. 22